Adult ADHD screening: ASRS-v1.1 — what it shows and what it doesn't replace

Adult ADHD: what we are actually measuring

The search "adult ADHD test" is a growing trend. Behind it is usually a person who recognized themselves in a TikTok thread, saw a childhood acquaintance in the description, and is trying to understand whether there is something structural in years of "not getting along with deadlines, boredom, and six-month projects". It is not a clinical question in the strict sense — but it begins with the right one: is there a valid way to check?

Adult ADHD is not "childhood ADHD that didn't go away" — it is a distinct diagnostic category recognized in both DSM-5 and ICD-11. The disorder moved from "childhood" to "neurodevelopmental disorder presenting in childhood and often persisting into adulthood". The criteria are adapted to adult tasks (career, relationships, finances, time management), but the symptom core is the same: attention-regulation deficits and/or hyperactive-impulsive behavior, onset before age 12, persisting ≥ 6 months, with functional impact in ≥ 2 life domains.

Why the diagnosis gets missed

The central clinical pattern of "adult ADHD" — it rarely arrives first. Anxiety, depression, burnout, sleep problems, career crisis show up first. That is not random. WHO World Mental Health Surveys (Fayyad et al., 2017, n=26,744 across 20 countries) yielded cross-national current adult ADHD prevalence of 2.8%; only a minority received treatment specifically targeting ADHD itself. The US NCS-R (Kessler et al., 2006, n=3,199) gave 4.4% current adult ADHD with the same pattern: the majority of cases were untreated for ADHD per se, although many individuals had received care for comorbid anxiety, depression, or substance disorders.

Long-undiagnosed ADHD generates a chronic "I don't match myself" feeling — and that feeds anxious-depressive layers. If a therapist works on anxiety or depression alone without asking "how about attention and impulsivity since childhood?", the structural layer stays invisible. A global meta-analysis (Song et al., 2021): persistent adult ADHD = 2.58% of the world population (≈140 million adults); symptomatic adult ADHD = 6.76% (≈366 million). The symptomatic pool is almost three times the persistent — these are people with clinically meaningful attention and impulsivity problems who don't quite reach the full DSM-5 diagnosis but are still functionally impaired.

There is also a stubborn opposite myth — "children grow out of it". In the 16-year follow-up of the landmark MTA study (Sibley et al., 2022, n=558), only 9.1% of the sample reached sustained remission. 90% continued to experience residual symptoms around age 25; 63.8% showed fluctuating "remission–recurrence" patterns; only 10.8% had persistent full-criteria ADHD throughout. In other words: "grew out of it" is the rare trajectory, not the modal one.

"Adult ADHD is prevalent, seriously impairing, and highly comorbid but vastly under-recognized and undertreated across countries and cultures."— Fayyad J. et al., Attention Deficit and Hyperactivity Disorders, 2017, 9(1):47–65

ASRS-v1.1: the 6-item brief screen

ASRS-v1.1 (Adult ADHD Self-Report Scale) was developed by WHO in collaboration with the Kessler-Adler-Spencer group (Kessler et al., 2005, *Psychological Medicine*). The scale contains 18 items mapped onto DSM-IV ADHD criteria. Part A — 6 items selected via stepwise logistic regression — turned out to be the most predictive of a positive structured-clinical-interview diagnosis. This is the "ASRS short screen" freely distributed by WHO.

Psychometrics of the 6-item screener in the original Kessler 2005 sample (n=154 from NCS-R, oversampling childhood ADHD): sensitivity 68.7%, specificity 99.5%, total classification accuracy 97.9%, κ = 0.76 against blind clinical DSM-IV ratings. It is a highly specific screen: few false positives, but it can miss some true positives (false negatives ≈ 30%). That is not a bug — it is calibration for the general population, where low baseline prevalence requires high specificity to avoid flooding the system with pseudo-positives.

• Completion time: 1–2 minutes (Part A) or 5 minutes (full 18)
• Use: first-line filter for further diagnostic assessment
• A positive screen is a trigger for an interview, not a diagnosis
• Free distribution via WHO; an official Russian translation exists
• Part A works better as a screener than the full 18 items (Kessler 2005)

ASRS-5 and the full 18 items: what they add

In 2017 an updated version appeared — ASRS-5 (Ustun et al., 2017, *JAMA Psychiatry*). It is a recalibration for DSM-5 criteria (which expanded onset from "before age 7" to "before age 12" and removed several other restrictions). A machine-learning Risk-Calibrated Supersparse Linear Integer Model chose a new 6-item set and weights. In the general population: sensitivity 91.4%, specificity 96.0%, AUC = 0.94, PPV = 67.3%. In a clinical sample (NYU Langone): sensitivity 91.9%, specificity 74.0%, AUC = 0.83, PPV = 82.8%. ASRS-5 is a more sensitive screen than classic ASRS-v1.1 while preserving good specificity.

A practically important caveat: ASRS-v1.1 and ASRS-5 are two different scales, both live, both in use. ASRS-v1.1 is the classic DSM-IV WHO version (Kessler 2005). ASRS-5 is the updated DSM-5 version (Ustun 2017). Clinical literature and Soveria use the classic ASRS-v1.1 — it has more accumulated normative data and translations; ASRS-5 catches more cases but is less established in international practice. Don't mix them in a single workflow.

The full 18 items (Part A + Part B) give a profile, not a single sum: 9 inattention items, 9 hyperactivity-impulsivity items. Part A covers both axes (4 inattention + 2 impulsivity) but doesn't split them into subscales. The long version answers the "which presentation predominates" question — inattentive, hyperactive-impulsive, or combined. The purely inattentive type gets lost in epidemiology — less visible to others, but with strong impact on work and learning. The pure hyperactive-impulsive type is rare in adults, although impulsivity remains a core trait. The combined type is the most common and usually the most functionally disabling.

A critical methodological limitation: ASRS does not assess development. DSM-5 requires ADHD symptoms to be present before age 12 — and ASRS shows the current picture, not childhood. So a positive ASRS without evidence of childhood manifestations is a reason to check the differential, not to diagnose adult ADHD. The retrospective piece is covered by the Wender Utah Rating Scale (see next section).

What ASRS doesn't replace: DIVA-5, CAARS, WURS

ASRS is a screen. After a positive result, formal diagnostic assessment is needed. Three instruments cover that task, and they complement rather than duplicate each other.

DIVA-5 (Diagnostic Interview for ADHD in Adults) is a semi-structured DSM-5 diagnostic interview. It covers 18 symptom criteria plus childhood-onset confirmation plus functional impact in ≥ 2 areas. Administration time is ~60–90 minutes by an experienced clinician. In a Korean validation (Hong et al., 2020, n=279): diagnostic accuracy 92%, sensitivity 91.30%, specificity 93.62% against a reference standard (MINI Plus + board-certified psychiatrists). In a Farsi validation (Amani et al., 2020, n=120): SCID-5 diagnostic agreement = 81.66%, test-retest and inter-rater reliability good to excellent. Recommended by the European Consensus (Kooij et al., 2019). Translated into Russian via the DIVA Foundation.

CAARS (Conners' Adult ADHD Rating Scales, Conners 1999) — a normative self-report and observer-rated profile. The long version (CAARS-S:L) has 66 items covering DSM-IV symptoms and four factors (Inattention, Hyperactivity-Impulsivity, ADHD Index, Problems). Unlike ASRS, CAARS provides age- and sex-normed scores — answering the question "how severe are the symptoms relative to a same-age, same-sex population". A licensed paid instrument from MHS.

WURS (Wender Utah Rating Scale, Ward et al., 1993) — a retrospective instrument: the adult patient rates their own childhood symptoms. Used for the DSM-5 "onset before age 12" criterion. In the short WURS-8 (Das et al., 2016, n=1,014): AUC > 0.8 for predicting adult ADHD diagnosis — comparable to the long WURS-25. Important clinical caveat: many WURS items are nonspecific (mood instability, anxiety, conduct problems in childhood). Only the "inattention/hyperactivity" factors map directly to ADHD; the rest can be confounders. WURS narrows the hypothesis — it does not confirm the diagnosis.

• ASRS-v1.1 — screening (free, WHO, ~5 min)
• DIVA-5 — structured DSM-5 interview (Kooij 2019 European Consensus, ~60–90 min)
• CAARS — normative self + observer profile (licensed, MHS)
• WURS — retrospective childhood assessment (AUC > 0.8 for predicting adult ADHD)

Differential diagnosis: anxiety, depression, bipolarity

The ADHD symptom core overlaps with what other diagnoses generate. Concentration drops with anxiety; impulsivity shows up in hypomanic episodes; "can't make myself start" is a description of depression. So a positive ASRS is the start of a differential conversation, not its end.

ADHD vs bipolar II — clinically the most dangerous confusion. In a large Korean sample (Joo et al., 2012, n=1,305: 108 BD-I, 41 BD-II, 101 MDD, 1,055 controls), the bipolar II group had the highest WURS scores of all groups — higher than BD-I and MDD. Childhood impulsivity and inattention predict adult BD-II more strongly than BD-I. So a positive WURS in an adult with "high energy and drive" episodes is a reason for bipolar screening (MDQ, HCL-32), not an immediate adult-ADHD diagnosis. Stimulant medications used for ADHD can trigger hypomania in occult bipolarity — a clinically consequential decision that cannot ride on ASRS alone.

Practical orientation points for the clinician.

• ADHD vs anxiety: in ADHD attention "slips" outside of stress contexts (a chronic pattern since childhood); in anxiety, only in stress contexts, usually with an episode-onset age
• ADHD vs depression: in ADHD anhedonia is not dominant and there is no generalized loss of interest; in depression, motivational decline is global, not symptom-specific
• ADHD vs bipolar II: ADHD hyperactivity is constant from childhood; hypomania is episodic (≥4 days), with altered sleep, euphoria, and goal-directed activity. WURS-positive is a cue to add MDQ
• ADHD vs "burnout": if "burnout" has lasted decades and symptoms reach back to school years — it isn't burnout. Burnout is an episodic response to chronic stress; it has a beginning

What to do with a positive screen

A positive ASRS is not a diagnosis. It's an argument to look deeper. A few typical workflows for private practice.

• Client with anxiety/depression and insufficient treatment response: ASRS as part of an extended assessment. If positive — retrospective WURS + referral for DIVA-5 (psychiatrist) or CAARS
• Client self-suspects ADHD: ASRS-v1.1 (Part A) as first step. Positive → structured interview; negative → pivot to differential (anxiety / depression / bipolarity / burnout)
• Tracking response to ADHD treatment: full 18-item ASRS every 4–8 weeks to follow change across both domains (inattention vs hyperactivity-impulsivity)
• Preventive screening in the general population: not recommended as routine — low base rate yields high false-positive share and inefficient use of clinical time

A short but important note on the Russian-language context. ASRS-v1.1 has an official WHO Russian translation and is freely distributed. DIVA-5 has been translated into Russian by the DIVA Foundation. However, formally published psychometric validations of ASRS-v1.1 or DIVA-5 in Russian-speaking samples are not currently found in PubMed. For clinical practice this means: use standardized instruments and international psychometric data as a reference, but always confirm diagnosis through clinical interview with cultural context in mind. Don't claim "an officially RF-validated version" — that fact is not in the published literature.

A closing point — about stigma and evidence. Faraone and colleagues (2021) summarize in the World Federation of ADHD International Consensus Statement 208 empirically supported propositions about ADHD and emphasize: misconceptions about ADHD stigmatize affected people, reduce credibility of providers, and prevent or delay treatment. Screening via a validated instrument is not a "trendy diagnosis"; it is the way to recognize a clinical reality that otherwise stays nameless and untreated for tens of millions of adults.